Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Philip S. Low
AddedFeb 18, 2024
UpdatedMay 31, 2026
Philip S. Low

Philip S. Low

Founder, On Target Laboratories

CrunchbaseLinkedInThe Org

Philip S. Low's Career

On Target Laboratories
On Target Laboratories

Northbrook, IL, US

Founder
Umoja Biopharma
Umoja Biopharma

Seattle, WA, US

Co-Founder
Eradivir
Eradivir

West Lafayette, IN, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Philip S. Low's Career

On Target Laboratories
On Target Laboratories
Series C$111.7M752010Northbrook, IL, US
Founder

Leadership at On Target Laboratories

Fritz FrenchFritz FrenchBoard Member
Bernie HaffeyBernie HaffeyBoard Member
Benjamin LundgrenBenjamin LundgrenCEO
Umoja Biopharma
Umoja Biopharma
Series B$263M2032019Seattle, WA, US
Co-Founder

Leadership at Umoja Biopharma

Ryan CrismanRyan CrismanCo-Founder
Andrew ScharenbergAndrew ScharenbergCo-Founder
Valentin BarsanValentin BarsanBoard Member

Similar to Umoja Biopharma

INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Thunder BiotechThunder BiotechProvo, UT, USCancer Treatmentest. 2016Thunder BiotechProvo, UT, US · est. 2016

Thunder Biotech: Innovating cancer treatment through biotechnology and immune system empowerment.

Pre-Seed · $24.4M23
ImmunomeImmunomeExton, PA, USCancer Therapiesest. 2008ImmunomeExton, PA, US · est. 2008

Immunome, a Philadelphia-based biotech company, develops innovative cancer immunotherapies.

Public · $218.9M48
Imvaq TherapeuticsImvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8
Eradivir
Eradivir
Angel$256k92020West Lafayette, IN, US
Co-Founder

Leadership at Eradivir

Martin LowMartin LowCo-Founder
Isaac BarchasIsaac BarchasBoard Member

Similar to Eradivir

Exavir TherapeuticsExavir TherapeuticsAntiviral Therapeuticsest. 2020Exavir Therapeuticsest. 2020

Exavir Therapeutics: A preclinical biotech firm focused on eradicating HIV and other viruses through nanomedicine.

Seed · $7M3
CoviCept TherapeuticsCoviCept TherapeuticsSan Diego, CA, USTherapeuticsest. 2020CoviCept TherapeuticsSan Diego, CA, US · est. 2020

Developing small molecule to inhibit RNA virus spread.

Seed · $2.3M6
Evrys BioEvrys BioDoylestown, PA, USAntiviral Therapyest. 2012Evrys BioDoylestown, PA, US · est. 2012

US-based Evrys Bio enhances sirtuins' natural ability to combat infections with unique antiviral therapy.

Series C · $34.8M18
IconOVir BioIconOVir BioSan Diego, CA, USOncolytic Virusest. 2018IconOVir BioSan Diego, CA, US · est. 2018

IconOVir Bio: A preclinical biotech firm innovating personalized oncolytic virus cancer therapies.

Series A · $77M8

Philip S. Low's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Philip S. Low

Philipp MewsPhilipp MewsCo-Founder · EpiVarioPhilip KantoffPhilip KantoffBoard Member · Memorial Sloan Kettering Cancer CenterLars SteinmetzLars SteinmetzCo-Founder · LevitasBioKlaus FruehKlaus FruehCo-Founder · Vir BiotechnologyLawrence S. PhillipsLawrence S. PhillipsCo-Founder · DiasystAndrei GudkovAndrei GudkovCo-Founder · Cleveland BioLabs